PostEra
PostEra uses its AI platform Proton to speed up the discovery and optimization of small-molecule drug candidates for biopharma partners and internal programs. Proton is an end-to-end machine learning platform that optimizes the Design‑Make‑Test cycle using chemistry foundation models, active learning, synthetic route design, and proprietary chemistry data. The company operates as a B2B SaaS and partnership-led biopharma, running co-discovery collaborations and milestone/royalty deals with pharmaceutical companies while advancing internal pipelines in areas like women’s health, fertility, oncology, obesity, and virology. PostEra integrates state-of-the-art synthesis and ML-driven design to improve candidate quality and reduce iteration time. It partners with large pharma and research institutions at scale, with multiple multi-year collaborations and programs for pandemic preparedness.
PostEra
PostEra uses its AI platform Proton to speed up the discovery and optimization of small-molecule drug candidates for biopharma partners and internal programs. Proton is an end-to-end machine learning platform that optimizes the Design‑Make‑Test cycle using chemistry foundation models, active learning, synthetic route design, and proprietary chemistry data. The company operates as a B2B SaaS and partnership-led biopharma, running co-discovery collaborations and milestone/royalty deals with pharmaceutical companies while advancing internal pipelines in areas like women’s health, fertility, oncology, obesity, and virology. PostEra integrates state-of-the-art synthesis and ML-driven design to improve candidate quality and reduce iteration time. It partners with large pharma and research institutions at scale, with multiple multi-year collaborations and programs for pandemic preparedness.
TL;DR
What they do: AI-driven drug discovery using Proton, an ML platform for medicinal chemistry
Business model: B2B SaaS and partnership-led co-discovery collaborations plus internal drug programs
Founded: 2019
Funding (reported): $26M total equity/grant financing reported
Key partners: Multi-year collaborations with Pfizer and Amgen; NIH funding
